

# ElÅ¼bieta Senkus

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/887849/publications.pdf>

Version: 2024-02-01

77  
papers

9,999  
citations

126907

33  
h-index

85541

71  
g-index

81  
all docs

81  
docs citations

81  
times ranked

11846  
citing authors

#	ARTICLE	IF	CITATIONS
1	European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. <i>Lancet Oncology</i> , The, 2022, 23, e21-e31.	10.7	117
2	High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer: results of comprehensive re-evaluation of multi-institutional case series. <i>Pathology</i> , 2022, 54, 269-278.	0.6	4
3	Management Strategies for Hyperglycemia Associated with the Î±-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. <i>Cancers</i> , 2022, 14, 1598.	3.7	16
4	Mobile applications for early breast cancer chemotherapy-related symptoms reporting and management: A scoping review. <i>Cancer Treatment Reviews</i> , 2022, 105, 102364.	7.7	8
5	miRNA signatures of prognostic significance in single hormone receptor-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e12544-e12544.	1.6	0
6	EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i> -mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1109-TPS1109.	1.6	2
7	Comparison of claudin-3 and claudin-4 expression in bilateral and unilateral breast cancer. <i>Neoplasma</i> , 2021, 68, 283-289.	1.6	2
8	OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline <i>BRCA1/2</i> mutations and high-risk HER2-negative early breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, LBA1-LBA1.	1.6	26
9	Lost but Not Least—Novel Insights into Progesterone Receptor Loss in Estrogen Receptor-Positive Breast Cancer. <i>Cancers</i> , 2021, 13, 4755.	3.7	7
10	Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 100, 102264.	7.7	29
11	De-escalation of axillary irradiation for early breast cancer – Has the time come?. <i>Cancer Treatment Reviews</i> , 2021, 101, 102297.	7.7	16
12	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. <i>ESMO Open</i> , 2020, 5, e000793.	4.5	113
13	microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers Is Mainly Dependent on HER2 Status—A Pilot Study. <i>Diagnostics</i> , 2020, 10, 617.	2.6	7
14	The requirements of a specialist breast centre. <i>Breast</i> , 2020, 51, 65-84.	2.2	111
15	Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. <i>Breast</i> , 2020, 52, 8-16.	2.2	188
16	ER-/PgR+ breast cancer is a separate entity characterized by distinct phenotype: Comprehensive reevaluation of cases from Polish and Hungarian centers.. <i>Journal of Clinical Oncology</i> , 2020, 38, e12554-e12554.	1.6	2
17	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , 2019, 120, 20-30.	2.8	75
18	OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. <i>Annals of Oncology</i> , 2019, 30, 558-566.	1.2	493

#	ARTICLE	IF	CITATIONS
19	Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1194-1220.	1.2	1,241
20	ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. <i>Radiotherapy and Oncology</i> , 2019, 137, 159-166.	0.6	80
21	Locally Advanced Breast Cancer. , 2018, , 567-578.		0
22	Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management. , 2018, , 579-594.		1
23	Estrogen receptor-negative progesterone receptor-positive breast cancer â€œ Nobody's landâ€œ or just an artifact?. <i>Cancer Treatment Reviews</i> , 2018, 67, 78-87.	7.7	46
24	4th ESOâ€œESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). <i>Annals of Oncology</i> , 2018, 29, 1634-1657.	1.2	891
25	EORTC QLQ-C30 (QLQ-C30) symptoms in patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib vs chemotherapy treatment of physicianâ€™s choice (TPC) in OlympiAD.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1045-1045.	1.6	3
26	Olaparib versus chemotherapy treatment of physicianâ€™s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1052-1052.	1.6	10
27	Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis focused on cell cycle regulation. <i>Histology and Histopathology</i> , 2018, 33, 55-64.	0.7	1
28	3rd ESOâ€œESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). <i>Annals of Oncology</i> , 2017, 28, 16-33.	1.2	865
29	Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 523-533.	27.0	2,256
30	Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. <i>Cancer Treatment Reviews</i> , 2017, 53, 98-110.	7.7	101
31	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). <i>Breast</i> , 2017, 35, 203-217.	2.2	203
32	Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatersen and chemotherapy for patients with advanced urothelial cancer. <i>Annals of Oncology</i> , 2017, 28, 2481-2488.	1.2	24
33	New horizon in breast cancer therapy: highlights from the European Society for Medical Oncology. <i>ESMO Open</i> , 2017, 2, e000204.	4.5	0
34	Over-treatment in metastatic breast cancer. <i>Breast</i> , 2017, 31, 309-317.	2.2	25
35	OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA4-LBA4.	1.6	4
36	OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline <i>BRCA</i> mutation (gBRCAm).. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA4-LBA4.	1.6	28

#	ARTICLE	IF	CITATIONS
37	Breast Cancer in Young Women - News from the BCY3 Consensus Conference. <i>Breast Care</i> , 2016, 11, 432-435.	1.4	0
38	Vinflunine vs gemcitabine versus vinflunine vs carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). <i>Annals of Oncology</i> , 2016, 27, 449-454.	1.2	45
39	A call back to reality!. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 67-68.	27.6	3
40	Management of locally advanced breast cancer – perspectives and future directions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 147-162.	27.6	113
41	Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 904-910.	0.8	52
42	The need for post-mastectomy radiotherapy in patients with IBC. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 370-370.	27.6	0
43	First-line randomized phase II study of gemcitabine/cisplatin plus apatosen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 4503-4503.	1.6	5
44	Czy wydłużona pooperacyjna hormonoterapia powinna być standardowym postępowaniem u chorych na raka piersi? Głos na TAK. <i>Nowotwory</i> , 2015, 65, 59-61.	0.3	0
45	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Annals of Oncology</i> , 2014, 25, 1871-1888.	1.2	402
46	Are bilateral breast cancers and breast cancers coexisting with ovarian cancer different from solitary tumors? A paired immunohistochemical analysis aimed at intrinsic tumor phenotype. <i>Pathology International</i> , 2014, 64, 508-517.	1.3	3
47	Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. <i>Psycho-Oncology</i> , 2014, 23, 173-182.	2.3	55
48	Synchronous and metachronous metastatic breast cancer – Two incarnations of the same beast?. <i>Breast</i> , 2014, 23, 1.	2.2	4
49	Time for more optimism in metastatic breast cancer?. <i>Cancer Treatment Reviews</i> , 2014, 40, 220-228.	7.7	59
50	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Breast</i> , 2014, 23, 489-502.	2.2	269
51	Breast cancer units – Improvement in care or expensive wishful thinking?. <i>Breast</i> , 2014, 23, 199-200.	2.2	2
52	Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4534-4534.	1.6	2
53	Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 353-63.	0.5	9
54	International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO) – MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. <i>Breast</i> , 2013, 22, 203-210.	2.2	77

#	ARTICLE	IF	CITATIONS
55	Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype. <i>Breast</i> , 2013, 22, 425-430.	2.2	1
56	Management of Adenoid Cystic Carcinoma of the Breast: A Rare Cancer Network Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 2118-2124.	0.8	58
57	1st International consensus guidelines for advanced breast cancer (ABC 1). <i>Breast</i> , 2012, 21, 242-252.	2.2	291
58	Cardiovascular effects of systemic cancer treatment. <i>Cancer Treatment Reviews</i> , 2011, 37, 300-311.	7.7	183
59	International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?. <i>Journal of the National Cancer Institute</i> , 2010, 102, 456-463.	6.3	325
60	Response: Re: International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2010, 102, 207-208.	6.3	0
61	International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1174-1181.	6.3	202
62	Sunitinib in breast cancer: Friend or foe. <i>Breast</i> , 2009, 18, 211-212.	2.2	1
63	Phyllodes Tumor of the Breast. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 492-500.	0.8	205
64	Exacerbation of diabetes related to exemestane treatment. <i>Acta OncolÅ³gica</i> , 2008, 47, 1167-1169.	1.8	2
65	Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. <i>Annals of Oncology</i> , 2008, 19, 1090-1096.	1.2	168
66	Cardiac Involvement at Presentation of NonÅ“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1010-1011.	1.6	19
67	BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. <i>Oncology Reports</i> , 2008, 19, 263-8.	2.6	51
68	Cardiovascular effects of breast cancer radiotherapy. <i>Cancer Treatment Reviews</i> , 2007, 33, 578-593.	7.7	91
69	Outcome and prognostic factors in breast sarcoma: A multicenter study from the rare cancer network. <i>Radiotherapy and Oncology</i> , 2007, 85, 355-361.	0.6	107
70	Changes in lateral dimensions of irradiated volume and their impact on the accuracy of dose delivery during radiotherapy for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2006, 79, 304-309.	0.6	17
71	Intraocular malignant teratoid medulloepithelioma in an adult: clinicopathological case report and review of the literature. <i>Acta Ophthalmologica</i> , 2006, 84, 259-262.	0.3	28
72	The effects of tamoxifen on the female genital tract. <i>Cancer Treatment Reviews</i> , 2004, 30, 291-301.	7.7	59

#	ARTICLE	IF	CITATIONS
73	Radiotherapy for breast cancer in patients undergoing breast reconstruction or augmentation. <i>Cancer Treatment Reviews</i> , 2004, 30, 671-682.	7.7	21
74	Second lower genital tract squamous cell carcinoma following cervical cancer. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2000, 79, 765-770.	2.8	3
75	Patient-related factors determining geometry of intracavitary applicators and pelvic dose distribution during cervical cancer brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 37, 531-536.	0.8	13
76	Alveolar Rhabdomyosarcoma of the Uterine Cervix. <i>Gynecologic Oncology</i> , 1996, 63, 398-403.	1.4	30
77	Epithelioid Sarcoma of the Bartholin's Gland Primarily Diagnosed as Vulvar Carcinoma. <i>Gynecologic Oncology</i> , 1994, 54, 393-395.	1.4	24